First reported by ft.com
Novartis to buy UK biotech in $1.5bn deal
Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis
1h ago· 3 min readenNews
Summary
Myricx Bio, a cancer therapy spinout from the Francis Crick Institute and Imperial College London, has agreed to be acquired by Novartis in a deal valued at up to US$1.5 billion, including a US$1.1 billion upfront cash payment plus potential milestone payments. The announcement was made by life sciences venture capital firm Brandon Capital.
Source
bskyCancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartiscrick.ac.ukKey quotes
· 2 pulledMyricx Bio, a cancer therapy spinout based on research carried out at the Francis Crick Institute and Imperial College London, has reached an agreement to be acquired by Novartis.
Announced today by the life sciences venture capital firm Brandon Capital, the transaction is valued at up to US$1.5 billion including an upfront cash payment of US$1.1 billion plus potential milestone payment
Myricx Bio, a cancer therapy spinout based on research carried out at the Francis Crick Institute and Imperial College London, has reached an agreement to be acquired by Novartis.
You might also wanna read
Novartis to buy UK biotech in $1.5bn deal
ft.com·6h ago
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
STAT·1h ago
Anne Wojcicki's Nonprofit Acquires 23andMe for $305 Million
Anne Wojcicki's nonprofit, TTAM Research Institute, has successfully outbid Regeneron Pharmaceuticals to acquire 23andMe for $305 million, i
cnbc.com·1y agoAdBiotech Becomes No. 2 Shareholder of Pet Healthcare Firm Onhil
Seoul Economic Daily·6h ago
Celltrion Poised for Profitability Leap on New Biosimilars
Seoul Economic Daily·15h ago
Nura raises $73.8M to target ALS through a unique target
biospace.com·13d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.